AUTL Autolus Therapeutics plc

27.18
+0.81  (+3%)
Previous Close 26.37
Open 26.38
Price To Book 5.26
Market Cap 1091207446
Shares 40,147,441
Volume 9,448
Short Ratio
Av. Daily Volume 90,867

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1 data due late-2019/early 2020.
AUTO4
T-cell lymphoma
Phase 1/2 data presented at ASH December 2018.
AUTO3
Relapsed or refractory diffuse large B-celllymphoma (DLBCL)
Phase 1/2 trial initiated 3Q 2017. Phase 1 part of trial to be completed 4Q 2019.
AUTO2
Relapsed or refractory multiple myeloma
Phase 1 data due at AACR 2019 noted 8/9 molecular complete responses.
AUTO1
Acute lymphoblastic leukemia (ALL)
Phase 1/2 trial for TRBC2-positive T-cell lymphoma to be initiated pending positive AUTO4 data.
AUTO5
T-cell lymphoma
Phase 2 part of trial to be initiated 2H 2019.
AUTO3 - (AMELIA)
Acute Lymphoblastic Leukemia

Latest News

  1. Autolus Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional American Depositary Shares
  2. What Kind Of Shareholder Owns Most Autolus Therapeutics plc (NASDAQ:AUTL) Stock?
  3. Autolus Therapeutics (AUTL) Catches Eye: Stock Jumps 5.6%
  4. Autolus Announces Pricing of Public Offering
  5. Autolus Announces Proposed Public Offering in the United States
  6. Arix Bioscience plc - Autolus Presents Initial AUTO1 Data at AACR
  7. Initial Results from Autolus Therapeutics’ ALLCAR19 Phase 1/2 Trial in Adult Acute Lymphoblastic Leukemia Presented at the AACR Annual Meeting
  8. Arix Bioscience plc - Autolus Announces Conference Call to Discuss AUTO1 ALLCAR19 Data Presentation at the AACR Annual Meeting 2019
  9. Autolus Therapeutics Announces Conference Call to Discuss AUTO1 ALLCAR19 Data Presentation at the AACR Annual Meeting 2019
  10. Autolus Therapeutics Unveils Expanded Next Generation Technology and Pipeline and Provides Key Update on AUTO3 Program in Pediatric ALL at R&D Day
  11. Autolus Therapeutics to Host R&D Day on March 26, 2019
  12. Autolus Therapeutics to Present at the Cowen and Company 39th Annual Healthcare Conference
  13. Autolus Therapeutics to Present New Data on AUTO1 at the American Association of Cancer Research (AACR) Annual Meeting 2019
  14. Vineti announces strategic partnership with Autolus Therapeutics to support delivery of novel T cell therapies
  15. Autolus Therapeutics Reports Financial and Operational Results for the Transition Period from October 1 to December 31, 2018
  16. Autolus Therapeutics to Announce Financial Results for the Transition Period from October 1, 2018 to December 31, 2018 and Host Conference Call on February 25, 2019
  17. Arix Bioscience plc: Autolus Announces Updated Results From CARPALL Trial
  18. Autolus Therapeutics Announces Updated Results from Ongoing CARPALL Trial of Pediatric Acute Lymphoblastic Leukemia Presented at the EHA 1st European CAR T Cell Meeting in Paris
  19. Alexandria Fully Leases New Built-to-Suit Facility to Autolus
  20. Biotech to create 170 jobs, invest $28M in new Rockville HQ